Detalles de la búsqueda
1.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol
; 170: 38-45, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610380
2.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol
; 168: 157-165, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36442427
3.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706643
4.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol
; 169: 98-105, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525930
5.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol
; 172: 65-71, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958197
6.
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
Gynecol Oncol
; 170: 334, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906375
7.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mol Cancer Ther
; 22(12): 1404-1412, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676984
Resultados
1 -
7
de 7
1
Próxima >
>>